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Abstract 
Background: FOXL2 encodes a forkhead transcription factor whose mutations are responsible 
for the Blepharophimosis-Ptosis-Epicanthus inversus Syndrome (BPES), involving 
craniofacial/palpebral abnormalities often associated with premature ovarian failure (POF). 
Results: We describe a FOXL2 variant (p.Gly187Asp) in a case of POF without BPES. The 
subcellular localization of FOXL2-G187D was normal but its transactivation capacity tested on 
two reporter promoters potentially relevant to the ovary was significantly lower than that of 
normal FOXL2. However, FOXL2-G187D was able to strongly activate a reporter construct 
driven by the promoter of Osr2 (odd-skipped related 2 transcription factor), which we have 
suggested to be a crucial target of FOXL2 in the craniofacial region. This is compatible with the 
absence of BPES in our patient.  
Conclusions: Our data provide evidence in favor of the implication of FOXL2 variants in non-
syndromic POF and confirm the regulatory interaction between FOXL2 and OSR2 whose 
perturbation might contribute to the palpebral abnormalities observed in BPES patients.  
Short Report 
FOXL2 is a single-exon gene encoding a forkhead transcription factor1 expressed in the ovarian 
somatic compartment and peri-ocular tissues2. In humans, its mutations cause the 
Blepharophimosis-Ptosis-Epicanthus inversus Syndrome (BPES), which involves 
craniofacial/palpebral abnormalities associated or not with premature ovarian failure (POF)3. 
 
Here, we study the effects of a FOXL2 variant detected in a POF case without BPES. Clinically, 
the 27 year-old patient of Tunisian origin, presented with secondary amenorrhea. She had a normal 
pubertal development and no history of diabetes, pelvic surgery, radiation or autoimmunity. 
Consanguinity and familial history of infertility were excluded. She had high FSH (45 IU/L; 
normal menopausal range: 25–160 IU/L) and LH (35 IU/L; normal menopausal range: 11.3–40 
IU/L) levels and low E2 (20 pg/mL; normal menopausal range <55 pg/mL). Cytogenetic analysis 
showed a normal 46,XX karyotype. Pelvic and ultrasound examination showed normal uterus and 
ovaries with several small follicles. The patient had none of the typical features of BPES (A signed 
informed consent is available from the JMG website). 
 
Direct sequencing of the FOXL2 coding region (performed as previously described4) revealed the 
presence of the heterozygous variant c.560G>A, inherited from her father, leading to the amino 
acid substitution p.Gly187Asp (FOXL2-G187D) in a highly conserved segment, C-terminal to the 
forkhead DNA-binding domain (Figure 1). This variant was absent in 110 control chromosomes. 
To assess the potential deleterious effect of the amino acid change we used the SIFT software 
(http://blocks.fhcrc.org/sift/SIFT.html). SIFT uses protein sequence conservation data to calculate 
the probability of a substitution of being deleterious. Scores lower than 0.05 suggest a potential 
pathogenicity. The score of p.Gly187Asp, obtained using the alignment shown in Figure 1, was 0. 
The substitution p.Gly187Asp implies an important change in polarity. Glycine is a small neutral 
amino acid whereas aspartate is acidic and negatively charged at pH 7. Interestingly, Tyr186 is 
predicted to be phosphorylatable (http://www.cbs.dtu.dk/services/NetPhosK/). Therefore, we 
hypothesize that the negative charge of the side chain of aspartate might interfere with the post-
translational modification process or mimic the modification itself, perturbing ovarian-specific 
protein interactions and/or regulations. 
 
To assess subcellular localization and transcriptional activity of FOXL2-G187D, we performed 
transfection experiments and luciferase reporter assays as previously described5,6. The FOXL2-
G187D variant fused to the green fluorescent protein displayed a typical nuclear staining, 
indistinguishable from that of normal FOXL2. From a functional perspective, FOXL2-G187D was 
found to activate the promoter of FOXL2 itself and the FOXL2-specific artificial promoter 
2xFLRE-luc (containing 2 FOXL2 response elements upstream of a minimal CMV promoter)6, 
though significantly less strongly than the normal protein. The p.Ile84Ser mutant, responsible for a 
type I BPES7, was used as a negative control and was, as expected, unable to transactivate our 
luciferase reporters. We have recently suggested that a positive feedback loop of FOXL2 (which 
activates its own promoter) might be important in response to oxidative stress in the ovary8. Thus, 
we hypothesize that a lowered transactivation capacity of FOXL2-G187D on ovarian targets might 
explain the ovarian phenotype in our patient (Figure 2 A, B). However, the effects of this variant is 
expected to be promoter-dependent, as previously shown for other mutants5,6, and as shown below 
for the third reporter promoter that we tested. 
 
We have previously suggested that, in the craniofacial region, the encoding odd-skipped related 2 
transcription factor (OSR2) should be a crucial target of FOXL29. Osr2 is, as Foxl2, highly 
expressed in the murine periocular mesenchyma10,11. Moreover, as described for Foxl2-/- mice, 
Osr2-/- mutant neonates exhibit open eyelids with similar abnormalities10,11. Unfortunately, no data 
concerning the Osr2-/- ovary are available yet10,12. In agreement with our hypothesis and with the 
absence of an eyelid phenotype in our patient (and in her mutation-carrier father), we found that 
FOXL2-G187D was able to strongly activate a reporter construct driven by the Osr2 promoter 
(pOSR2) described by Kawai et al 200512. Coherently, the FOXL2-I84S mutant found in a BPES I 
patient failed to transactivate pOsr2 (Figure 2 C). Since no second BPES locus has been reported 
thus far, it is unlikely that mutations in OSR2 itself might contribute directly to BPES. However, 
regulatory mutations perturbing the interaction FOXL2-pOSR2 are worth being screened in BPES 
patients with normal FOXL2. 
 
The fact that FOXL2-G187D may be either normal or hypomorph suggests that it can behave as a 
susceptibility variant whose activity might be shifted up or down by modifier genes, leading to 
normal ovarian function or POF, respectively. Given our functional evidence, it would be 
interesting to formally assess the association between p.Gly187Asp and POF.  
 
A previous mutation screening has detected a 30 bp deletion removing 10 out of 14 alanines of 
the FOXL2 polyAlanine tract (i.e. FOXL2-Ala4) and the substitution p.Tyr258Asn in two POF 
patients13,14. Interestingly, neither mutation was identified in 200 control chromosomes. 
However, the fact that the p.Tyr258Asn variant was maternally inherited and that the patient 
carrying the FOXL2-Ala4 variant spontaneously conceived and delivered two babies did not 
allow a formal causal implication of these alterations in absence of functional assays at the time 
of these studies. Both variants might display incomplete penetrance or lead, at least, to partial 
fertility recovery after appropriate treatments. Thus, it would be interesting to assess the 
functional impact for both alterations. 
 
Taken together, our results provide functional evidence in favor of the implication of FOXL2 
variants in non-syndromic POF and confirm the regulatory interaction between FOXL2 and OSR2, 
whose perturbation might contribute to the palpebral phenotype in BPES. In our opinion, a more 
systematic genetic screening of FOXL2 mutations is of interest in non-syndromic POF, to improve 
genetic counseling and to better understand the molecular etiology of this frequent pathology. 
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Figure legends. 
Figure 1: FOXL2 sequence alignment around Gly187. The alignment involves sequences from 
vertebrates ranging from amphibian and fishes to mammals. The relevant Gly187 residue is 
highlighted within a frame. The immediately previous highly conserved Tyr/Y residue is predicted 
to be phosphorylatable. The negative charge of aspartate in FOXL2-Gly187Asp might interfere 
with the post-translational modification process or mimic the modification itself. 
 
Figure 2. Luciferase assays using three reporter promoters. For transfections, we used granulosa-
like KGN cells and each experiment was performed in 5 replicates. The variant p.Ile84Ser was 
obtained by fusion PCR as previously described5,6. A) Activity on the FOXL2-specific artificial 
promoter 2xFLRE-luc (containing 2 FOXL2 response elements upstream of a minimal CMV 
promoter)6, B) Activity on the promoter of FOXL2 itself and C) Activity on pOsr2. In all cases 
ANOVAs were significant (p<0.001). Post-hoc Tuckey HSD tests showed that the mutant 
p.Ile84Ser always behaved no differently than the empty control vector, while G187D had a 
significant activity, through lower than the wild-type/WT protein for 2xFLRE-luc and pFOLX2-
luc (A,B). Interestingly, in the case of pOsr2-luc (C), G187D had an activity even stronger than 
the WT. In all cases, p-values were at least < 0.05.  
 
Homo_sapiens MKRPFRPPPAHFQPGKGLFGAGGAAGGCGVAGAGADGYGYLAPPKYLQ
Pan_troglodytes MKRPFRPPPAHFQPGKGLFGAGGAAGGCGVAGAAADGYGYLAPPKYLQ
Bos_taurus MKRPFRPPPAHFQPGKGLFGAGGAAGGCGVAGAGADGYGYLAPPKYLQ
Capra_hircus MKRPFRPPPAHFQPGKGLFGAGGAAGGCGVAGAGADGYGYLAPPKYLQ
Pteropus_vampyrus MKRPFRPPPAHFQPGKGLFGAAGAAGGCGVAGAGTDGYGYLAPPKYLQ
Sus_scrofa MKRPFRPPPAHFQPGKGLFGAGGAAGGCGVAGAGADGYGYLAPPKYLQ
Dasypus_novemcinctus MKRPFRPPPAHFQPGKGLFAAGGAAAGCGVAGAGADSYGYLAPPKYLQ
Ellobius_lutescens MKRPFRPPPAHFQPGKGLFGSGGAAGGCGVAGAGADGYGYLAPPKYLQ
Oryctolagus_cuniculus MKRPFRPPPAHFQPGKGLFGAAGAAGGCGVAGAGADGYGYLAPPKYLQ
Mus_musculus MKRPFRPPPAHFQPGKGLFGSGGAAGGCGVPGAGADGYGYLAPPKYLQ
Epinephelus_merra MKRPFRPPPTHFQP--------------GKSLFGGDGYGYLSPPKYLQ
Oreochromis_aureus MKRPFRPPPTHFQP--------------GKALFGGDSYGYLSPPKYLQ
Oryzias_luzonensis MKRPFRPPPTHFQP--------------GKALFGGDGYGYLSPPKYLQ
Oncorhynchus_mykiss MKRPFRPPPTHFQP--------------GKSLFGGDGYGYLSPPKYLQ
Danio_rerio MKRPFRPPPTHFQP--------------GKSLFGGEGYGYLSPPKYLQ
Silurus_meridionalis MKRPFRPPTSHFQA--------------GKSIFGGDSYGYLSPPKYLQ
Xenopus_laevis MKRPFRPPPTHFQA--------------GKSLFGSDTYGYLSPPKYLQ
Rana_rugosa MKRPFRPPPTHFQA--------------GKSLFSSDTYGYLSPPKYLQ
Gallus_gallus MKRPFRPPPTHFQP--------------GKSLFGPDGYGYLSPPKYLQ
Scyliorhinus_canicula MKRPFRPPPTHFQHS-------------KAALFASDSYGYIGPPKYLQ
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